Anti-tumor activities of lipids and lipid analogues and their development as potential anticancer drugs

Pharmacology and Therapeutics

Volumn 150, Issue , 2015, Pages 109-128

  Murray, Michael ^a   Hraiki, Adam ^a   Bebawy, Mary ^b   Pazderka, Curtis ^b   Rawling, Tristan ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

Alkyl phospholipid; Epoxide isostere; Lipid based anticancer agent; PUFA epoxide; Tumor apoptosis; Tumor proliferation

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; BUTYRIC ACID; CAPECITABINE; CYTOCHROME P450; CYTOCHROME P450 2J2; DEXAMETHASONE; EDELFOSINE; FATTY ACID; ICOSANOID; ILMOFOSINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JACARIC ACID; LENALIDOMIDE; LIPID; LIPOXYGENASE; MILTEFOSINE; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; OMEGA 3 FATTY ACID; PALMITIC ACID; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE A2; PROSTAGLANDIN SYNTHASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VACCENIC ACID; XANTHINE OXIDASE; PHOSPHOLIPID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CARCINOGENESIS; CELL CYCLE REGULATION; CELL DEATH; CELL MEMBRANE; CELL PROLIFERATION; CELL VIABILITY; CLINICAL TRIAL (TOPIC); DRUG POTENCY; DRUG TRANSFORMATION; ENZYME INHIBITION; ESTERIFICATION; GROWTH REGULATION; HUMAN; INTRACELLULAR SIGNALING; LIPID RAFT; MITOGENESIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; ANIMAL; DRUG EFFECTS; LIPID METABOLISM; METABOLISM; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DEATH; CELL PROLIFERATION; FATTY ACIDS; HUMANS; LIPID METABOLISM; LIPIDS; NEOPLASMS; PHOSPHOLIPIDS; SIGNAL TRANSDUCTION;

EID: 84928406173     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2015.01.008     Document Type: Review

References (280)

1. S.H. Abou-el-Ela, K.W. Prasse, R.L. Farrell, R.W. Carroll, A.E. Wade, and O.R. Bunce Effects of D, L-2-difluoromethylornithine and indomethacin on mammary tumor promotion in rats fed high n-3 and/or n-6 fat diets Cancer Res 49 1989 1434 1440
2. C.S. Adamson, and E.O. Freed Novel approaches to inhibiting HIV-1 replication Antiviral Res 85 2010 119 141
3. W.A. Alaynick Nuclear receptors, mitochondria and lipid metabolism Mitochondrion 8 2008 329 337
4. J.D. Altenburg, and R.A. Siddiqui Omega-3 polyunsaturated fatty acids down-modulate CXCR4 expression and function in MDA-MB-231 breast cancer cells Mol Cancer Res 7 2009 1013 1020
5. E.S. Antonarakis, E.I. Heath, J.R. Walczak, W.G. Nelson, H. Fedor, and A.M. De Marzo Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers J Clin Oncol 27 2009 4986 4993
6. A. Argiris, E. Cohen, T. Karrison, B. Esparaz, A. Mauer, and R. Ansari A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer Cancer Biol Ther 5 2006 766 770
7. K. Athenstaedt, and G. Daum The life cycle of neutral lipids: synthesis, storage and degradation Cell Mol Life Sci 63 2006 1355 1369
8. I. Avis, S.H. Hong, A. Martinez, T. Moody, Y.H. Choi, and J. Trepel Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions FASEB J 15 2001 2007 2009
9. I.M. Avis, M. Jett, T. Boyle, M.D. Vos, T. Moody, and A.M. Treston Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling J Clin Invest 97 1996 806 813
10. H.H. Bailey, M.R. Mahoney, D.S. Ettinger, W.J. Maples, P.M. Fracasso, and A.M. Traynor Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma Cancer 107 2006 2462 2467
11. G. Baillat, C. Siret, E. Delamarre, and J. Luis Early adhesion induces interaction of FAK and Fyn in lipid domains and activates raft-dependent Akt signaling in SW480 colon cancer cells Biochim Biophys Acta 1783 2008 2323 2331
12. G. Barrera Oxidative stress and lipid peroxidation products in cancer progression and therapy ISRN Oncol 2012 2012 137289
13. O.J. Becher, D. Hambardzumyan, T.R. Walker, K. Helmy, J. Nazarian, and S. Albrecht Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma Cancer Res 70 2010 2548 2557
14. J.C. Bendell, T.J. Ervin, N.N. Senzer, D.A. Richards, I. Firdaus, and A.C. Lockhart Results of the X-PECT study: a phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC) J Clin Oncol 30 Suppl.: abstr LBA3501 2012
15. J.C. Bendell, J. Nemunaitis, S.J. Vukelja, C. Hagenstad, L.T. Campos, and R.C. Hermann Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer J Clin Oncol 29 2011 4394 4400
16. W.E. Berdel, U. Fink, and J. Rastetter Clinical phase I pilot study of the alkyl lysophospholipid derivative ET-18-OCH3 Lipids 22 1987 967 969
17. P. Bernardi, D. Penzo, and L. Wojtczak Mitochondrial energy dissipation by fatty acids Vitam Horm 65 2002 97 126
18. I.M. Berquin, Y. Min, R. Wu, J. Wu, D. Perry, and J.M. Cline Modulation of prostate cancer genetic risk by ω-3 and ω-6 fatty acids J Clin Invest 117 2007 1866 1875
19. B. Bhatia, C.J. Maldonado, S. Tang, D. Chandra, and R.D. Klein Subcellular localization and tumor-suppressive functions of 15-lipoxygenase 2 (15-LOX2) and its splice variants J Biol Chem 278 2003 25091 25100
20. M.D. Brand, and D.G. Nicholls Assessing mitochondrial dysfunction in cells Biochem J 435 2011 297 312
21. R.S. Bresalier, R.S. Sandler, H. Quan, J.A. Bolognese, B. Oxenius, and K. Horgan Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 352 2005 1092 1102
22. R.M. Breyer Prostaglandin EP(1) receptor subtype selectivity takes shape Mol Pharmacol 59 2001 1357 1359
23. R.M. Breyer, C.K. Bagdassarian, S.A. Myers, and M.D. Breyer Prostanoid receptors: subtypes and signaling Annu Rev Pharmacol Toxicol 41 2001 661 690
24. G.L. Bundy, and J.M. Baldwin The synthesis of nitrogen-containing prostacyclin analogs Tetrahedron Lett 19 1978 1371 1374
25. G. Bundy, F. Lincoln, N. Nelson, J. Pike, and W. Schneider Novel prostaglandin syntheses Ann N Y Acad Sci 180 1971 76 90
26. G. Calviello, F. Di Nicuolo, S. Gragnoli, E. Piccioni, S. Serini, and N. Maggiano n-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and -2 and HIF-1α induction pathway Carcinogenesis 25 2004 2303 2310
27. K.O. Cameron, B.A. Lefker, M.Y. Chu-Moyer, D.T. Crawford, P.D. Jardine, and S.L. DeNinno Discovery of highly selective EP4 receptor agonists that stimulate new bone formation and restore bone mass in ovariectomized rats Bioorg Med Chem Lett 16 2006 1799 1802
28. H. Carpio, G.F. Cooper, J.A. Edwards, J.H. Fried, G.L. Garay, and A. Guzman Synthesis and gastric antisecretory properties of allenic 16-phenoxy-ω-tetranor prostaglandin E analogs Prostaglandins 33 1987 169 180
29. M.C. Cathcart, K. Gately, R. Cummins, E. Kay, K.J. O'Byrne, and G.P. Pidgeon Examination of thromboxane synthase as a prognostic indicator and therapeutic factor in non-small cell lung cancer Mol Cancer 10 2011 25
30. C. Cerella, C. Sobolewski, M. Dicato, and M. Diederich Targeting COX-2 expression by natural compounds: a promising alternative strategy to synthetic COX-2 inhibitors for cancer chemoprevention and therapy Biochem Pharmacol 80 2010 1801 1815
31. J.C. Chambard, R. Lefloch, J. Pouysségur, and P. Lenormand ERK implication in cell cycle regulation Biochim Biophys Acta 1773 2007 1299 1310
32. K.G. Chee, J. Longmate, D.I. Quinn, G. Chatta, J. Pinski, and P. Twardowski The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial Clin Genitourin Cancer 5 2007 433 437
33. J.K. Chen, J. Capdevila, and R.C. Harris Cytochrome P450 epoxygenase metabolism of arachidonic acid inhibits apoptosis Mol Cell Biol 21 2001 6322 6331
34. C. Chen, G. Li, W. Liao, J. Wu, L. Liu, and D. Ma Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo J Pharmacol Exp Ther 329 2009 908 918
35. C.L. Chen, C.F. Lin, W.T. Chang, W.C. Huang, C.F. Teng, and Y.S. Lin Ceramide induces p38 MAPK and JNK activation through a mechanism involving a thioredoxin-interacting protein-mediated pathway Blood 111 2008 4365 4374
36. S.Y. Cheranov, M. Karpurapu, D. Wang, B. Zhang, R.C. Venema, and G.N. Rao An essential role for SRC-activated STAT-3 in 14,15-EET-induced VEGF expression and angiogenesis Blood 111 2008 5581 5591
37. D.C. Cho, T.E. Hutson, W. Samlowski, P. Sportelli, B. Somer, and P. Richards Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy Cancer 118 2012 6055 6062
38. D.E. Christofferson, and J. Yuan Necroptosis as an alternative form of programmed cell death Curr Opin Cell Biol 22 2010 263 268
39. S. Clive, J. Gardiner, and R.C. Leonard Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma Cancer Chemother Pharmacol 44 Suppl. 1999 S29 S30
40. S. Colas, E. Germain, K. Arab, K. Maheo, C. Goupille, and P. Bougnoux α-Tocopherol suppresses mammary tumor sensitivity to anthracyclines in fish oil-fed rats Nutr Cancer 51 2005 178 183
41. S. Colas, K. Maheo, F. Denis, C. Goupille, C. Hoinard, and P. Champeroux Sensitization by dietary docosahexaenoic acid of rat mammary carcinoma to anthracyclines: a role for tumor vascularization Clin Cancer Res 12 2006 5879 5886
42. P.W. Collins, and S.W. Djuric Synthesis of therapeutically useful prostaglandin and prostacyclin analogs Chem Rev 93 1993 1533 1564
43. R. Colomer, and J.A. Menendez Mediterranean diet, olive oil and cancer Clin Transl Oncol 8 2006 15 21
44. K.D. Courtney, R.B. Corcoran, and J.A. Engelman The PI3K pathway as drug target in human cancer J Clin Oncol 28 2010 1075 1083
45. S. Crettol, N. Petrovic, and M. Murray Pharmacogenetics of phase I and phase II drug metabolism Curr Pharm Des 16 2010 204 219
46. M. Crul, H. Rosing, G.J. de Klerk, R. Dubbelman, M. Traiser, and S. Reichert Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours Eur J Cancer 38 2002 1615 1621
47. P.H. Cui, N. Petrovic, and M. Murray The ω-3 epoxide of eicosapentaenoic acid inhibits endothelial cell proliferation by p38 MAP kinase activation and cyclin D1/CDK4 down-regulation Br J Pharmacol 162 2011 1143 1155
48. P.H. Cui, T. Rawling, K. Bourget, T. Kim, C.C. Duke, and M.R. Doddareddy Antiproliferative and antimigratory actions of synthetic long chain n-3 monounsaturated fatty acids in breast cancer cells that overexpress cyclooxygenase-2 J Med Chem 55 2012 7163 7172
49. B. Dangi, M. Obeng, J.M. Nauroth, M. Teymourlouei, M. Needham, and K. Raman Biogenic synthesis, purification, and chemical characterization of anti-inflammatory resolvins derived from docosapentaenoic acid (DPAn-6) J Biol Chem 284 2009 14744 14759
50. M.A. de Pablo, S.A. Susin, E. Jacocot, N. Larochette, P. Costantini, and L. Ravagnan Palmitate induces apoptosis via a direct effect on mitochondria Apoptosis 4 1999 81 97
51. A. Degterev, M. Boyce, and J. Yuan A decade of caspases Oncogene 22 2003 8543 8567
52. A. Di Popolo, A. Memoli, A. Apicella, C. Tuccillo, A. di Palma, and P. Ricchi IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells Oncogene 19 2000 5517 5524
53. U. Diczfalusy, B.F. Kase, S.E. Alexson, and I. Björkhem Metabolism of prostaglandin F2α in Zellweger syndrome. Peroxisomal β-oxidation is of major importance for in vivo degradation of prostaglandins in humans J Clin Invest 88 1991 978 984
54. M.A. Dimopoulos, D. Weber, K.B. Delasalle, M. Keating, and R. Alexanian Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors Ann Oncol 6 1995 49 52
55. B.J. Druker, F. Guilhot, S.G. O'Brien, I. Gathmann, H. Kantarjian, and N. Gattermann Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2006 2408 2417
56. C.D. Duffy, and P.J. Guiry Recent advances in the chemistry and biology of stable synthetic Lipoxin analogues Med Chem Commun 1 2010 249 265
57. R. Dummer, M. Krasovec, J. Röger, H. Sindermann, and G. Burg Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas: results of a phase I/II study J Am Acad Dermatol 29 1993 963 970
58. C. Dumontet, L. Thomas, F. Berard, J.F. Gimonet, and B. Coiffier A phase II trial of miltefosine in patients with cutaneous T-cell lymphoma Bull Cancer 93 2006 E115 E118
59. H.R. Dyari, T. Rawling, K. Bourget, and M. Murray Synthetic ω-3 epoxyfatty acids as antiproliferative and pro-apoptotic agents in human breast cancer cells J Med Chem 57 2014 7459 7464
60. M.J. Edelman, D. Watson, X. Wang, C. Morrison, R.A. Kratzke, and S. Jewell Eicosanoid modulation in advanced lung cancer: Cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy: Cancer and Leukemia Group B Trial 30203 J Clin Oncol 26 2008 848 855
61. N.V. Eldho, S.E. Feller, S. Tristram-Nagle, I.V. Polozov, and K. Gawrisch Polyunsaturated docosahexaenoic versus docosapentaenoic acid. Differences in lipid matrix properties from the loss of one double bond J Am Chem Soc 125 2003 6409 6421
62. H.A. Elrod, Y.D. Lin, P. Yue, X. Wang, S. Lonial, and F.R. Khuri The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway Mol Cancer Ther 6 2007 2029 2038
63. H.A. Elrod, and S.Y. Sun PPARγ and apoptosis in cancer PPAR Res 2008 2008 704165
64. T.R. Elworthy, E.R. Brill, S.S. Chiou, F. Chu, J.R. Harris, and R.T. Hendricks Lactams as EP4 prostanoid receptor agonists. 3. Discovery of N-ethylbenzoic acid 2-pyrrolidinones as subtype selective agents J Med Chem 47 2004 6124 6127
65. N.J. Emenaker, G.M. Calaf, D. Cox, M.D. Basson, and N. Qureshi Short-chain fatty acids inhibit invasive human colon cancer by modulating uPA, TIMP-1, TIMP-2, mutant p53, Bcl-2, Bax, p21 and PCNA protein expression in an in vitro cell culture model J Nutr 131 2001 3041S 3046S
66. D.S. Ernst, E. Eisenhauer, N. Wainman, M. Davis, R. Lohmann, and T. Baetz Phase II study of perifosine in previously untreated patients with metastatic melanoma Invest New Drugs 23 2005 569 575
67. B. Escudier, T. Eisen, W.M. Stadler, C. Szczylik, S. Oudard, and M. Siebels Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
68. P. Fagone, and S. Jackowski Membrane phospholipid synthesis and endoplasmic reticulum function J Lipid Res 50 2009 S311 S316
69. J.R. Falck, R. Kodela, R. Manne, K.R. Atcha, N. Puli, and N. Dubasi 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition J Med Chem 52 2009 5069 5075
70. J.R. Falck, L.M. Reddy, Y.K. Reddy, M. Bondlela, U.M. Krishna, and Y. Ji 11,12-Epoxyeicosatrienoic acid (11,12-EET): structural determinants for inhibition of TNF-alpha-induced VCAM-1 expression Bioorg Med Chem Lett 13 2003 4011 4014
71. J.R. Falck, G. Wallukat, N. Puli, M. Goli, C. Arnold, and A. Konkel 17(R),18(S)-epoxyeicosatetraenoic acid, a potent eicosapentaenoic acid (EPA) derived regulator of cardiomyocyte contraction: structure-activity relationships and stable analogues J Med Chem 54 2011 4109 4118
72. J.K. Fauser, L.D. Prisciandaro, A.G. Cummins, and G.S. Howarth Fatty acids as potential adjunctive colorectal chemotherapeutic agents Cancer Biol Ther 11 2011 724 731
73. S.E. Feller, and K. Gawrisch Properties of docosahexaenoic-acid-containing lipids and their influence on the function of rhodopsin Curr Opin Struct Biol 15 2005 416 422
74. S.E. Feller, K. Gawrisch, and A.D. MacKerell Jr. Polyunsaturated fatty acids in lipid bilayers: intrinsic and environmental contributions to their unique physical properties J Am Chem Soc 124 2002 318 326
75. M. Fer, Y. Dréano, D. Lucas, L. Corcos, J.P. Salaün, and F. Berthou Metabolism of eicosapentaenoic and docosahexaenoic acids by recombinant human cytochromes P450 Arch Biochem Biophys 471 2008 116 125
76. W.D. Figg, M. Monga, D. Headlee, A. Shah, C.H. Chau, and C. Peer A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms Cancer Chemother Pharmacol 74 2014 955 967
77. J. Folkman What is the evidence that tumors are angiogenesis-dependent? J Natl Cancer Inst 82 1990 4 6
78. C.A.M. Fraga, A.L.P. Miranda, and E.J. Barreiro Design and synthesis of a new 4-oxa-8ω-11-deoxy-5,6-dihydroprostacyclin analogue Chem Pharm Bull 44 1996 2157 2161
79. J. Fried, D.K. Mitra, M. Nagarajan, and M.M. Mehrotra 10,10-Difluoro-13-dehydroprostacyclin: a chemically and metabolically stabilized potent prostacyclin J Med Chem 23 1980 234 237
80. D.R. Friedman, M.C. Lanasa, P.H. Davis, S.D. Allgood, K.M. Matta, and D.M. Brander Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies Leuk Lymphoma 55 2014 1067 1075
81. S. Fu, B.T. Hennessy, C.S. Ng, Z. Ju, K.R. Coombes, and J.K. Wolf Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer Gynecol Oncol 126 2012 47 53
82. C.D. Funk Prostaglandins and leukotrienes: advances in eicosanoid biology Science 294 2001 1871 1875
83. C. Gajate, E. Del Canto-Janez, A.U. Acuna, F. Amat-Guerri, E. Geijo, and A.M. Santos-Beneit Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis J Exp Med 200 2004 353 365
84. C. Gajate, F. Gonzalez-Camacho, and F. Mollinedo Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells PLoS One 4 2009 e5044
85. C. Gajate, M. Matos-da-Silva, el-H. Dakir, R.I. Fonteriz, and J. Alvarez Antitumor alkyl-lysophospholipid analog edelfosine induces apoptosis in pancreatic cancer by targeting endoplasmic reticulum Oncogene 31 2012 2627 2639
86. C. Gajate, and F. Mollinedo Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts Blood 109 2007 711 719
87. X. Gao, D.J. Grignon, T. Chbihi, A. Zacharek, Y.Q. Chen, and W. Sakr Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer Urology 46 1995 227 237
88. Y. Gao, H. Ishiyama, M. Sun, K.L. Brinkman, X. Wang, and J. Zhu The alkylphospholipid, perifosine, radiosensitizes prostate cancer cells both in vitro and in vivo Radiat Oncol 6 2011 39
89. C. Garcia-Ruiz, A. Colell, M. Mari, A. Morales, and J.C. Fernandez-Checa Direct effect of ceramide on the mitochondrial electron transport chain leads to generation of reactive oxygen species. Role of mitochondrial glutathione J Biol Chem 272 1997 11369 11377
90. J. Gasmi, and J.T. Sanderson Growth inhibitory, antiandrogenic, and pro-apoptotic effects of punicic acid in LNCaP human prostate cancer cells J Agric Food Chem 58 2010 12149 12156
91. J. Gasmi, and J.T. Sanderson Jacaric acid and its octadecatrienoic acid geoisomers induce apoptosis selectively in cancerous human prostate cells: a mechanistic and 3-D structure-activity study Phytomedicine 20 2013 734 742
92. I.M. Ghobrial, A. Roccaro, F. Hong, E. Weller, N. Rubin, and R. Leduc Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia Clin Cancer Res 16 2010 1033 1041
93. J. Ghosh, and C.E. Myers Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells Proc Natl Acad Sci U S A 95 1998 13182 13187
94. B.J. Giantonio, C. Derry, C. McAleer, J.J. McPhillips, and P.J. O'Dwyer Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly two-hour infusion in patients with advanced solid tumors Clin Cancer Res 10 2004 1282 1288
95. M.A. Gimbrone Jr., S.B. Leapman, R.S. Cotran, and J. Folkman Tumor dormancy in vivo by prevention of neovascularization J Exp Med 136 1972 261 276
96. M.H. Glickman, and J.P. Klinman Lipoxygenase reaction mechanism: demonstration that hydrogen abstraction from substrate precedes dioxygen binding during catalytic turnover Biochemistry 35 1996 12882 12892
97. G. Gloire, S. Legrand-Poels, and J. Piette NF-κB activation by reactive oxygen species: fifteen years later Biochem Pharmacol 72 2006 1493 1505
98. I. Gojo, A. Perl, S. Luger, M.R. Baer, K.J. Norsworthy, and K.S. Bauer Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome Invest New Drugs 31 2013 1217 1227
99. M.E. Grossmann, N.K. Mizuno, M.L. Dammen, T. Schuster, A. Ray, and M.P. Cleary Eleostearic Acid inhibits breast cancer proliferation by means of an oxidation-dependent mechanism Cancer Prev Res 2 2009 879 886
100. M.E. Grossmann, N.K. Mizuno, T. Schuster, and M.P. Cleary Punicic acid is an omega-5 fatty acid capable of inhibiting breast cancer proliferation Int J Oncol 36 2010 421 426
101. F.P. Guengerich Cytochrome P450s and other enzymes in drug metabolism and toxicity AAPS J 8 2006 E101 E111
102. A. Guidetti, C. Carlo-Stella, S.L. Locatelli, W. Malorni, R. Mortarini, and S. Viviani Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases Clin Cancer Res 20 2014 5641 5651
103. W.J. Guilford, J.G. Bauman, W. Skuballa, S. Bauer, G.P. Wei, and D. Davey Novel 3-oxa lipoxin A4 analogues with enhanced chemical and metabolic stability have anti-inflammatory activity in vivo J Med Chem 47 2004 2157 2165
104. S. Gupta, M. Srivastava, N. Ahmad, K. Sakamoto, D.G. Bostwick, and H. Mukhtar Lipoxygenase-5 is overexpressed in prostate adenocarcinoma Cancer 91 2001 737 743
105. J. Gutknecht Proton conductance caused by long-chain fatty acids in phospholipid bilayer membranes J Membr Biol 106 1988 83 93
106. D.C. Guttridge, C. Albanese, J.Y. Reuther, R.G. Pestell, and A.S. Baldwin Jr. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1 Mol Cell Biol 19 1999 5785 5799
107. S. Haas, C. Pierl, V. Harth, B. Pesch, S. Rabstein, and T. Brüning Expression of xenobiotic and steroid hormone metabolizing enzymes in human breast carcinomas Int J Cancer 119 2006 1785 1791
108. J.Z. Haeggström, and C.D. Funk Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease Chem Rev 111 2011 5866 5898
109. J.F. Hancock Lipid rafts: contentious only from simplistic standpoints Nat Rev Mol Cell Biol 7 2006 456 462
110. W.E. Hardman Omega-3 fatty acids to augment cancer therapy J Nutr 132 2002 3508S 3512S
111. W.E. Hardman, C.P. Avula, G. Fernandes, and I.L. Cameron Three percent dietary fish oil concentrate increased efficacy of doxorubicin against MDA-MB 231 breast cancer xenografts Clin Cancer Res 7 2001 2041 2049
112. G. Hawcroft, P.M. Loadman, A. Belluzzi, and M.A. Hull Effect of eicosapentaenoic acid on E-type prostaglandin synthesis and EP4 receptor signaling in human colorectal cancer cells Neoplasia 12 2010 618 627
113. B.G. Heerdt, M.A. Houston, G.M. Anthony, and L.H. Augenlicht Mitochondrial membrane potential (ΔΨ) in the coordination of p53-independent proliferation and apoptosis pathways in human colonic carcinoma cells Cancer Res 58 1998 2869 2875
114. B.G. Heerdt, M.A. Houston, and L.H. Augenlicht Short-chain fatty acid initiated cell cycle arrest and apoptosis of colonic epithelial cells is linked to mitochondrial function Cell Growth Differ 8 1997 523 532
115. M.C. Heinrich, C.L. Corless, G.D. Demetri, C.D. Blanke, M. von Mehren, and H. Joensuu Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor J Clin Oncol 21 2003 4342 4349
116. G. Henke, V. Meier, L.H. Lindner, H. Eibl, M. Bamberg, and C. Belka Effects of ionizing radiation in combination with erufosine on T98G glioblastoma xenograft tumours: a study in NMRI nu/nu mice Radiat Oncol 7 2012 172
117. D.B. Herrmann, H.A. Neumann, W.E. Berdel, M.E. Heim, M. Fromm, and D. Boerner Phase I trial of the thioether phospholipid analogue BM 41.440 in cancer patients Lipids 22 1987 962 966
118. M. Hildebrand, W. Krause, H. Fabian, T. Koziol, and H.H. Neumayer Pharmacokinetics of iloprost in patients with chronic renal failure and on maintenance haemodialysis Int J Clin Pharmacol Res 10 1990 285 292
119. M. Hildebrand, T. Staks, A. Schütt, and H. Matthes Pharmacokinetics of 3H-cicaprost in healthy volunteers Prostaglandins 37 1989 259 273
120. S.H. Hong, I. Avis, M.D. Vos, A. Martinez, A.M. Treston, and J.L. Mulshine Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors Cancer Res 59 1999 2223 2228
121. L.C. Hsi, L.C. Wilson, and T.E. Eling Opposing effects of 15-lipoxygenase-1 and -2 metabolites on MAPK signaling in prostate. Alteration in peroxisome proliferator-activated receptor gamma J Biol Chem 277 2002 40549 40556
122. E. Hvattum, S. Bergseth, C.N. Pedersen, J. Bremer, A. Aarsland, and R.K. Berge Microsomal oxidation of dodecylthioacetic acid (a 3-thia fatty acid) in rat liver Biochem Pharmacol 41 1991 945 953
123. J.D. Imig, A. Elmarakby, K. Nithipatikom, S. Wei, J.H. Capdevila, and V.R. Tuniki Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions Front Physiol 1 2010 157
124. B. Inceoglu, S.L. Jinks, A. Ulu, C.M. Hegedus, K. Georgi, and K.R. Schmelzer Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways Proc Natl Acad Sci U S A 105 2008 18901 18906
125. P.O. Iversen, D.R. Sørensen, K.J. Tronstad, O.A. Gudbrandsen, A.C. Rustan, and R.K. Berge A bioactively modified fatty acid improves survival and impairs metastasis in preclinical models of acute leukemia Clin Cancer Res 12 2006 3525 3531
126. P. Jacob 3rd, and A.T. Shulgin Sulfur analogues of psychotomimetic agents. Monothio analogues of mescaline and isomescaline J Med Chem 24 1981 1348 1353
127. A.J. Jakubowiak, P.G. Richardson, T. Zimmerman, M. Alsina, J.L. Kaufman, and M. Kandarpa Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study Br J Haematol 158 2012 472 480
128. L.R. Jensen, K. Berge, T.F. Bathen, H. Wergedahl, S.A. Schonberg, and A. Bofin Effect of dietary tetradecylthioacetic acid on colon cancer growth studied by dynamic contrast enhanced MRI Cancer Biol Ther 6 2007 1810 1816
129. J.G. Jiang, C.L. Chen, J.W. Card, S. Yang, J.X. Chen, and X.N. Fu Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors Cancer Res 65 2005 4707 4715
130. J.G. Jiang, Y.G. Ning, C. Chen, D. Ma, Z.J. Liu, and S. Yang Cytochrome P450 epoxygenase promotes human cancer metastasis Cancer Res 67 2007 6665 6674
131. W.G. Jiang, G. Watkins, A. Douglas-Jones, and R.E. Mansel Reduction of isoforms of 15-lipoxygenase (15-LOX)-1 and 15-LOX-2 in human breast cancer Prostaglandins Leukot Essent Fatty Acids 74 2006 235 245
132. T. Kambe, T. Maruyama, Y. Nakai, H. Yoshida, H. Oida, and T. Maruyama Discovery of novel prostaglandin analogs as potent and selective EP2/EP4 dual agonists Bioorg Med Chem 20 2012 2235 2251
133. T. Kamijo, T. Sato, Y. Nagatomi, and T. Kitamura Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines Int J Urol 8 2001 S35 S39
134. F. Kamp, and J.A. Hamilton pH gradients across phospholipid membranes caused by fast flip-flop of unionized fatty acids Proc Natl Acad Sci U S A 89 1992 11367 11370
135. R.A. Karmali, P. Reichel, L.A. Cohen, T. Terano, A. Hirai, and Y. Tamura The effects of dietary ω-3 fatty acids on the DU-145 transplantable human prostatic tumor Anticancer Res 17 1987 1173 1180
136. U.P. Kelavkar, J.B. Nixon, C. Cohen, D. Dillehay, and T.E. Eling Overexpression of 15-lipoxygenase-1 in PC-3 human prostate cancer cells increases tumorigenesis Carcinogenesis 22 2001 1765 1773
137. E. Klann, and E. Thiels Modulation of protein kinases and protein phosphatases by reactive oxygen species: implications for hippocampal synaptic plasticity Prog Neuropsychopharmacol Biol Psychiatry 23 1999 359 376
138. D.E. Kleiner, and W.G. Stetler-Stevenson Matrix metalloproteinases and metastasis Cancer Chemother Pharmacol 43 Suppl. 1999 S42 S51
139. M. Knowling, M. Blackstein, R. Tozer, V. Bramwell, J. Dancey, and N. Dore A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: a National Cancer Institute of Canada Clinical Trials Group trial Invest New Drugs 24 2006 435 439
140. S.S. Korshunov, O.V. Korkina, E.K. Ruuge, V.P. Skulachev, and A.A. Starkov Fatty acids as natural uncouplers preventing generation of O2- and H2O2 by mitochondria in the resting state FEBS Lett 435 1998 215 218
141. W. Krause, P.E. Schulze, and M. Totzek Pharmacokinetics of the stable prostacyclin analogue, nileprost, in the rat Prostaglandins Leukot Med 11 1983 241 257
142. A. Kumar, H.L. Fillmore, R. Kadian, W.C. Broaddus, G.W. Tye, and T.E. Van Meter The alkylphospholipid perifosine induces apoptosis and p21-mediated cell cycle arrest in medulloblastoma Mol Cancer Res 7 2009 1813 1821
143. A.C. Lee, and M. Murray Upregulation of human CYP2J2 in HepG2 cells by butylated hydroxyanisole is mediated by c-Jun and Nrf2 Mol Pharmacol 77 2010 987 994
144. N.B. Leighl, S. Dent, M. Clemons, T.A. Vandenberg, R. Tozer, and D.G. Warr A Phase 2 study of perifosine in advanced or metastatic breast cancer Breast Cancer Res Treat 108 2008 87 92
145. X. Leleu, X. Jia, J. Runnels, H.T. Ngo, A.S. Moreau, and M. Farag The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia Blood 110 2007 4417 4426
146. K.C. Leung, M.K. Hsin, J.S. Chan, J.H. Yip, M. Li, and B.C. Leung Inhibition of thromboxane synthase induces lung cancer death via increasing the nuclear p27 Exp Cell Res 315 2009 2974 2981
147. K.C. Leung, M.Y. Li, B.C. Leung, M.K. Hsin, T.S. Mok, and M.J. Underwood Thromboxane synthase suppression induces lung cancer cell apoptosis via inhibiting NF-κB Exp Cell Res 316 2010 3468 3477
148. T. Lin, X. Yin, Q. Cai, X. Fan, K. Xu, and L. Huang 13-Methyltetradecanoic acid induces mitochondrial-mediated apoptosis in human bladder cancer cells Urol Oncol 30 2012 339 345
149. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
150. S.L. Locatelli, A. Giacomini, A. Guidetti, L. Cleris, R. Mortarini, and A. Anichini Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts Leukemia 27 2013 1677 1687
151. V. Maillard, P. Bougnoux, P. Ferrari, M.L. Jourdan, M. Pinault, and F. Lavillonnière n-3 and n-6 fatty acids in breast adipose tissue and relative risk of breast cancer in a case-control study in Tours, France Int J Cancer 98 2002 78 83
152. M. Malumbres, and M. Barbacid To cycle or not to cycle: a critical decision in cancer Nat Rev Cancer 1 2001 222 231
153. N.Y. Marden, E. Fiala-Beer, S.H. Xiang, and M. Murray Role of Activator Protein-1 in the downregulation of the human CYP2J2 gene in hypoxia Biochem J 373 2003 669 680
154. Rde W. Marsh, C.M. Rocha Lima, D.E. Levy, E.P. Mitchell, K.M. Jr Rowland, and A.B. Benson 3rd A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma Am J Clin Oncol 30 2007 26 31
155. J. Matsukawa, A. Matsuzawa, K. Takeda, and H. Ichijo The ASK1-MAP kinase cascades in mammalian stress response J Biochem 136 2004 261 265
156. Y. Matsumura, T. Asai, T. Shimada, T. Nakayama, M. Urushihara, and Y. Morizawa Novel fluoroprostacyclin analogs with modified cycloalkylenyl chains. Highly potent and orally active anti-anginal agents Chem Pharm Bull 43 1995 353 355
157. S.G.A. McLaughlin, and J.P. Dilger Transport of protons across membranes by weak acids Physiol Rev 60 1980 825 863
158. E.B. Melian, and K.L. Goa Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension Drugs 62 2002 107 133
159. H. Meng, Y. Jin, H. Liu, L. You, C. Yang, and X. Yang SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt J Hematol Oncol 6 2013 18
160. A.H. Merrill Jr., and D.D. Jones An update of the enzymology and regulation of sphingomyelin metabolism Biochim Biophys Acta 1044 1990 1 12
161. U.R. Michaelis, B. Fisslthaler, M. Medhora, D. Harder, I. Fleming, and R. Busse Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR) FASEB J 17 2003 770 772
162. A. Miller, E. McGrath, C. Stanton, and R. Devery Vaccenic acid (t11-18:1) is converted to c9, t11-CLA in MCF-7 and SW480 cancer cells Lipids 38 2003 623 632
163. V. Milovic, I.C. Teller, L. Turchanowa, W.F. Caspary, and J. Stein Effect of structural analogues of propionate and butyrate on colon cancer cell growth Int J Colorectal Dis 15 2000 264 270
164. F. Mollinedo, M. Fernández, V. Hornillos, J. Delgado, F. Amat-Guerri, and A.U. Acuña Involvement of lipid rafts in the localization and dysfunction effect of the antitumor ether phospholipid edelfosine in mitochondria Cell Death Dis 2 2011 e158
165. F. Mollinedo, J.L. Fernandez-Luna, C. Gajate, B. Martin-Martin, A. Benito, and R. Martinez-Dalmau Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L) Cancer Res 57 1997 1320 1328
166. R.M. Moretti, M. Montagnani Marelli, A. Sala, M. Motta, and P. Limonta Activation of the orphan nuclear receptor RORalpha counteracts the proliferative effect of fatty acids on prostate cancer cells: crucial role of 5-lipoxygenase Int J Cancer 112 2004 87 93
167. E.T. Morgan Regulation of cytochromes P450 during inflammation and infection Drug Metab Rev 29 1997 1129 1188
168. O. Moussa, J.M. Riker, J. Klein, M. Fraig, P.V. Halushka, and D.K. Watson Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents Oncogene 27 2008 55 62
169. D.H. Munzenmaier, and D.R. Harder Cerebral microvascular endothelial cell tube formation: role of astrocytic epoxyeicosatrienoic acid release Am J Physiol Heart Circ Physiol 278 2000 H1163 H1167
170. M. Murakami, H. Naraba, T. Tanioka, N. Semmyo, Y. Nakatani, and F. Kojima Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2 J Biol Chem 275 2000 32783 32792
171. M. Murray In vitro and in vivo studies of the effect of vitamin E on microsomal cytochrome P450 in rat liver Biochem Pharmacol 42 1991 2107 2114
172. M. Murray Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes Int J Mol Med 3 1999 227 237
173. G.I. Murray, S. Patimalla, K.N. Stewart, I.D. Miller, and S.D. Heys Profiling the expression of cytochrome P450 in breast cancer Histopathology 57 2010 202 211
174. M. Murray, L. Zaluzny, and G.C. Farrell Impaired androgen 16α-hydroxylation in hepatic microsomes from carbon tetrachloride-cirrhotic male rats Gastroenterology 93 1987 141 147
175. I. Nagatsuka, N. Yamada, S. Shimizu, M. Ohira, H. Nishino, and S. Seki Inhibitory effect of a selective cyclooxygenase-2 inhibitor on liver metastasis of colon cancer Int J Cancer 100 2002 515 519
176. B.A. Narayanan, N.K. Narayanan, B. Simi, and B.S. Reddy Modulation of inducible nitric oxide synthase and related proinflammatory genes by the ω-3 fatty acid docosahexaenoic acid in human colon cancer cells Cancer Res 63 2003 972 979
177. N. Navarro-Tito, A. Soto-Guzman, L. Castro-Sanchez, R. Martinez-Orozco, and E.P. Salazar Oleic acid promotes migration on MDA-MB-231 breast cancer cells through an arachidonic acid-dependent pathway Int J Biochem Cell Biol 42 2010 306 317
178. K.C. Nicolaou, W.E. Barnette, G.P. Gasic, and R.L. Magolda 6,9-Thiaprostacyclin. A stable and biologically potent analogue of prostacyclin (PGI2) J Am Chem Soc 99 1977 7736 7738
179. D. Nie, M. Che, A. Zacharek, Y. Qiao, L. Li, and X. Li Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility Am J Pathol 164 2004 429 439
180. T. Nieto-Miguel, R.I. Fonteriz, L. Vay, C. Gajate, S. López-Hernández, and F. Mollinedo Endoplasmic reticulum stress in the proapoptotic action of edelfosine in solid tumor cells Cancer Res 67 2007 10368 10378
181. T. Nieto-Miguel, C. Gajate, and F. Mollinedo Differential targets and subcellular localization of antitumor alkyl-lysophospholipid in leukemic versus solid tumor cells J Biol Chem 281 2006 14833 14840
182. J.A. Oates, G.A. FitzGerald, R.A. Branch, E.K. Jackson, H.R. Knapp, and L.J. Roberts 2nd Clinical implications of prostaglandin and thromboxane A2 formation N Engl J Med 319 1988 689 698
183. E.H. Oliw Oxygenation of polyunsaturated fatty acids by cytochrome P450 monooxygenases Prog Lipid Res 33 1994 329 354
184. D.B. Ostrander, G.C. Sparagna, A.A. Amoscato, J.B. McMillin, and W. Dowhan Decreased cardiolipin synthesis corresponds with cytochrome c release in palmitate-induced cardiomyocyte apoptosis J Biol Chem 276 2001 38061 38067
185. D. Panigrahy, M.L. Edin, C.R. Lee, S. Huang, D.R. Bielenberg, and C.E. Butterfield Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice J Clin Invest 122 2012 178 191
186. V.A. Papadimitrakopoulou, W.N. William Jr., A.J. Dannenberg, S.M. Lippman, J.J. Lee, and F.G. Ondrey Pilot randomized phase II study of celecoxib in oral premalignant lesions Clin Cancer Res 14 2008 2095 2101
187. J.B. Park, C.S. Lee, J.H. Jang, J. Ghim, and Y.J. Kim Phospholipase signalling networks in cancer Nat Rev Cancer 12 2012 782 792
188. G.P. Pidgeon, M. Kandouz, A. Meram, and K.V. Honn Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells Cancer Res 62 2002 2721 2727
189. G.P. Pidgeon, J. Lysaght, S. Krishnamoorthy, J.V. Reynolds, K. O'Byrne, and D. Nie Lipoxygenase metabolism: roles in tumor progression and survival Cancer Metastasis Rev 26 2007 503 524
190. K.L. Pitter, C.J. Galban, S. Galban, O.S. Tehrani, F. Li, and N. Charles Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma PLoS One 6 2011 e14545
191. R. Piva, G. Belardo, and M.G. Santoro NF-κB: a stress-regulated switch for cell survival Antioxid Redox Signal 8 2006 478 486
192. A.S. Planting, G. Stoter, and J. Verweij Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer Eur J Cancer 29A 1993 518 519
193. E.M. Posadas, J. Gulley, P.M. Arlen, A. Trout, H.L. Parnes, and J. Wright A phase II study of perifosine in androgen independent prostate cancer Cancer Biol Ther 4 2005 1133 1137
194. M. Potente, U.R. Michaelis, B. Fisslthaler, R. Busse, and I. Fleming Cytochrome P450 2C9-induced endothelial cell proliferation involves induction of mitogen-activated protein (MAP) kinase phosphatase-1, inhibition of the c-Jun N-terminal kinase, and up-regulation of cyclin D1 J Biol Chem 277 2002 15671 15676
195. A. Pozzi, I. Macias-Perez, T. Abair, S. Wei, Y. Su, and R. Zent Characterization of 5,6- and 8,9-epoxyeicosatrienoic acids (5,6- and 8,9-EET) as potent in vivo angiogenic lipids J Biol Chem 280 2005 27138 27146
196. A. Pozzi, V. Popescu, S. Yang, S. Mei, M. Shi, and S.M. Puolitaival The anti-tumorigenic properties of peroxisomal proliferator-activated receptor-α are arachidonic acid epoxygenase-mediated J Biol Chem 285 2010 12840 12850
197. K. Rajamoorthi, H.I. Petrache, T.J. McIntosh, and M.F. Brown Packing and Viscoelasticity of polyunsaturated ω-3 and ω-6 lipid bilayers as seen by 2H NMR and X-ray diffraction J Am Chem Soc 127 2005 1576 1588
198. S. Rajput, and A. Wilber Roles of inflammation in cancer initiation, progression, and metastasis Front Biosci 2 2010 176 183
199. S.A. Reddy, J.H. Huang, and W.S. Liao Phosphatidylinositol 3-kinase as a mediator of TNF-induced NF-κB activation J Immunol 164 2000 1355 1363
200. P.G. Richardson, A. Nagler, D. Ben-Yehuda, A.Z. Badros, P. Hari, and R. Hajek Randomized placebo-controlled phase III study of perifosine combined with bortezomib and dexamethasone in relapsed, refractory multiple myeloma patients previously treated with bortezomib Am Soc Hematol 2013 Annual Meeting 2013 (abstr: 3189)
201. P.G. Richardson, J. Wolf, A. Jakubowiak, J. Zonder, S. Lonial, and D. Irwin Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial J Clin Oncol 29 2011 4243 4249
202. A. Robert, J.R. Schultz, J.E. Nezamis, and C. Lancaster Gastric antisecretory and antiulcer properties of PGE2, 15-methyl PGE2, and 16, 16-dimethyl PGE2. Intravenous, oral and intrajejunal administration Gastroenterology 70 1976 359 370
203. P.J. Roberts, and C.J. Der Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer Oncogene 26 2007 3291 3310
204. R.J. Roman P-450 metabolites of arachidonic acid in the control of cardiovascular function Physiol Rev 82 2002 131 185
205. D.P. Rose, and L.A. Cohen Effects of dietary menhaden oil and retinyl acetate on the growth of DU145 human prostatic adenocarcinoma cells transplanted into athymic nude mice Carcinogenesis 9 1988 603 605
206. D.P. Rose, and J.M. Connolly Dietary fat and breast cancer metastasis by human tumor xenografts Breast Cancer Res Treat 46 1997 225 237
207. D.P. Rose, and J.M. Connolly Regulation of tumor angiogenesis by dietary fatty acids and eicosanoids Nutr Cancer 37 2000 119 127
208. C.A. Rouzer, and L.J. Marnett Mechanism of free radical oxygenation of polyunsaturated fatty acids by cyclooxygenases Chem Rev 103 2003 2239 2304
209. A. Rübel, R. Handrick, L.H. Lindner, M. Steiger, H. Eibl, and W. Budach The membrane targeted apoptosis modulators erucylphosphocholine and erucylphosphohomocholine increase the radiation response of human glioblastoma cell lines in vitro Radiat Oncol 1 2006 6
210. G.A. Ruiter, S.F. Zerp, H. Bartelink, W.J. van Blitterswijk, and M. Verheij Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis Cancer Res 59 1999 2457 2463
211. H. Sakai, T. Suzuki, Y. Takahashi, M. Ukai, K. Tauchi, and T. Fujii Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane A2 FEBS Lett 580 2006 3368 3374
212. A. Salmon, S.W. Dodd, G.D. Williams, J.M. Beach, and M.F. Brown Configurational statistics of acyl chains in polyunsaturated lipid bilayers from deuterium NMR J Am Chem Soc 109 1987 2600 2609
213. P. Samadder, and G. Arthur Decreased sensitivity to 1-O-octadecyl-2-O-methyl-glycerophosphocholine in MCF-7 cells adapted for serum-free growth correlates with constitutive association of Raf-1 with cellular membranes Cancer Res 59 1999 4808 4815
214. K.A. Sarosiek, X. Chi, J.A. Bachman, J.J. Sims, J. Montero, and L. Patel BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response Mol Cell 51 2013 751 765
215. T.K. Schaaf, J.S. Bindra, J.F. Eggler, J.J. Plattner, A.J. Nelson, and M.R. Johnson N-(Methanesulfonyl)-16-phenoxyprostaglandin carboxamides: tissue-selective, uterine stimulants J Med Chem 24 1981 1353 1359
216. M. Schlame, D. Rua, and M.L. Greenberg The biosynthesis and functional role of cardiolipin Prog Lipid Res 39 2000 257 288
217. P.D. Schley, D.N. Brindley, and C.J. Field ω-3 PUFA alter raft lipid composition and decrease epidermal growth factor receptor levels in lipid rafts of human breast cancer cells J Nutr 137 2007 548 553
218. S. Schubbert, K. Shannon, and G. Bollag Hyperactive Ras in developmental disorders and cancer Nat Rev Cancer 7 2007 295 308
219. S.A. Schwartz, A. Hernandez, and B.M. Evers The role of NF-κB/IκB proteins in cancer; implications for novel treatment strategies Surg Oncol 8 1999 143 153
220. R.S. Seelan, C. Qian, A. Yokomizo, D.G. Bostwick, D.I. Smith, and W. Liu Human acid ceramidase is overexpressed but not mutated in prostate cancer Genes Chromosomes Cancer 29 2000 137 146
221. C.N. Serhan, J.F. Maddox, N.A. Petasis, I. Akritopoulou-Zanze, A. Papayianni, and H.R. Brady Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils Biochemistry 34 1995 14609 14615
222. T. Sessler, S. Healy, A. Samali, and E. Szegezdi Structural determinants of DISC function: new insights into death receptor-mediated apoptosis signalling Pharmacol Ther 140 2013 186 199
223. S.B. Shappell, W.E. Boeglin, S.J. Olson, S. Kasper, and A.R. Brash 15-Lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma Am J Pathol 155 1999 235 245
224. C.J. Sherr, and J.M. Roberts CDK inhibitors: positive and negative regulators of G1-phase progression Genes Dev 13 1999 1501 1512
225. S. Shimizu, A. Konishi, T. Kodama, and Y. Tsujimoto BH4 domain of antiapoptotic Bcl-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death Proc Natl Acad Sci U S A 97 2000 3100 3105
226. N. Shinohara, T. Tsuduki, J. Ito, T. Honma, R. Kijima, and S. Sugawara Jacaric acid, a linolenic acid isomer with a conjugated triene system, has a strong antitumor effect in vitro and in vivo Biochim Biophys Acta 1821 2012 980 988
227. I. Shureiqi, Y. Wu, D. Chen, X.L. Yang, B. Guan, and J.S. Morris The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis Cancer Res 65 2005 11486 11492
228. R.A. Siddiqui, K. Harvey, and W. Stillwell Anticancer properties of oxidation products of docosahexaenoic acid Chem Phys Lipids 153 2008 47 56
229. L.C. Silva, A.H. Futerman, and M. Prieto Lipid raft composition modulates sphingomyelinase activity and ceramide-induced membrane physical alterations Biophys J 96 2009 3210 3222
230. K. Simons, and D. Toomre Lipid rafts and signal transduction Nat Rev Mol Cell Biol 1 2000 31 39
231. C.H. Smorenburg, C. Seynaeve, M. Bontenbal, A.S. Planting, and H. Sindermann Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients Anticancer Drugs 11 2000 825 828
232. M. Sonoshita, K. Takaku, N. Sasaki, Y. Sugimoto, F. Ushikubi, and S. Narumiya Acceleration of intestinal polyposis through prostaglandin receptor EP2 in ApcΔ716 knockout mice Nat Med 7 2001 1048 1051
233. D.L. Soper, J.B. Milbank, G.E. Mieling, M.J. Dirr, A.S. Kende, and R. Cooper Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis J Med Chem 44 2001 4157 4169
234. O. Soubias, and K. Gawrisch Docosahexaenoyl chains isomerize on the sub-nanosecond time scale J Am Chem Soc 129 2007 6678 6679
235. A.A. Spector, and M.A. York Membrane lipid composition and cellular function J Lipid Res 26 1985 1015 1035
236. S. Stürzebecher, M. Haberey, B. Müller, E. Schillinger, G. Schröder, and W. Skuballa Pharmacological profile of a novel carbacyclin derivative with high metabolic stability and oral activity in the rat Prostaglandins 31 1986 95 109
237. M. Szymczak, M. Murray, and N. Petrovic Modulation of angiogenesis by ω-3 polyunsaturated fatty acids is mediated by cyclooxygenases Blood 111 2008 3514 3521
238. M. Taccone-Gallucci, S. Manca-di-Villahermosa, L. Battistini, R.G. Stuffler, M. Tedesco, and M. Maccarrone n-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity Kidney Int 69 2006 1450 1454
239. J.M. Terwogt, I.A. Mandjes, H. Sindermann, J.H. Beijnen, and W.W. ten Bokkel Huinink Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer Br J Cancer 79 1999 1158 1161
240. R. Tevar, D.H. Jho, T. Babcock, W.S. Helton, and N.J. Espat ω-3 fatty acid supplementation reduces tumor growth and vascular endothelial growth factor expression in a model of progressive non-metastasizing malignancy J Parenter Enteral Nutr 26 2002 285 289
241. B. Tilton, L. Ho, E. Oberlin, P. Loetscher, F. Baleux, and I. Clark-Lewis Signal transduction by CXC chemokine receptor 4. Stromal cell-derived factor 1 stimulates prolonged protein kinase B and extracellular signal-regulated kinase 2 activation in T lymphocytes J Exp Med 192 2000 313 324
242. K. Tobiume, A. Matsuzawa, T. Takahashi, H. Nishitoh, K. Morita, and K. Takeda ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis EMBO Rep 2 2001 222 228
243. G. Tortora, R. Caputo, V. Damiano, D. Melisi, R. Bianco, and G. Fontanini Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect Clin Cancer Res 9 2003 1566 1572
244. K.J. Tronstad, K. Berge, E. Dyroy, L. Madsen, and R.K. Berge Growth reduction in glioma cells after treatment with tetradecylthioacetic acid: changes in fatty acid metabolism and oxidative status Biochem Pharmacol 61 2001 639 649
245. K.J. Tronstad, B.T. Gjertsen, C. Krakstad, K. Berge, O.T. Brustugun, and S.O. Doskeland Mitochondrial-targeted fatty acid analog induces apoptosis with selective loss of mitochondrial glutathione in promyelocytic leukemia cells Chem Biol 10 2003 609 618
246. T. Tsuzuki, and Y. Kawakami Tumor angiogenesis suppression by α-eleostearic acid, a linolenic acid isomer with a conjugated triene system, via peroxisome proliferator-activated receptor γ Carcinogenesis 29 2008 797 806
247. T. Tsuzuki, Y. Tokuyama, M. Igarashi, and T. Miyazawa Tumor growth suppression by α-eleostearic acid, a linolenic acid isomer with a conjugated triene system, via lipid peroxidation Carcinogenesis 25 2004 1417 1425
248. U. Tüber, M. Brudny-Klöppel, U. Jakobs, C. Madetzki, and M. Mahler Pharmacokinetics of nocloprost in human volunteers and its relation to dose Eur J Clin Pharmacol 44 1993 497 500
249. C. Unger, W. Berdel, A.R. Hanauske, H. Sindermann, J. Engel, and K. Mross First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours Eur J Cancer 46 2010 920 925
250. A.H. van der Luit, S.R. Vink, J.B. Klarenbeek, D. Perrissoud, E. Solary, and M. Verheij A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells Mol Cancer Ther 6 2007 2337 2345
251. M.H. van der Sanden, M. Houweling, L.M. van Golde, and A.B. Vaandrager Inhibition of phosphatidylcholine synthesis induces expression of the endoplasmic reticulum stress and apoptosis-related protein CCAAT/enhancer-binding protein-homologous protein (CHOP/GADD153) Biochem J 369 2003 643 650
252. L. Van Ummersen, K. Binger, J. Volkman, R. Marnocha, K. Tutsch, and J. Kolesar A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer Clin Cancer Res 10 2004 7450 7456
253. A.J. Vecchio, D.M. Simmons, and M.G. Malkowski Structural basis of fatty acid substrate binding to cyclooxygenase-2 J Biol Chem 285 2010 22152 22163
254. K. Vermeulen, D.R. Van Bockstaele, and Z.N. Berneman The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer Cell Prolif 36 2003 131 149
255. J. Verweij, D. Gandia, A.S. Planting, G. Stoter, and J.P. Armand Phase II study of oral miltefosine in patients with squamous cell head and neck cancer Eur J Cancer 29A 1993 778 779
256. J. Verweij, K. Krzemieniecki, T. Kok, A. Poveda, C. van Pottelsberghe, and M. van Glabbeke Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult - an EORTC Soft Tissue and Bone Sarcoma Group Study Eur J Cancer 29A 1993 208 209
257. J. Verweij, A. Planting, M. van der Burg, and G. Stoter A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours J Cancer Res Clin Oncol 118 1992 606 608
258. P. Viatour, M.P. Merville, V. Bours, and A. Chariot Phosphorylation of NF-κB and IκB proteins: implications in cancer and inflammation Trends Biochem Sci 30 2005 43 52
259. S.R. Vink, J.H. Schellens, J.H. Beijnen, H. Sindermann, J. Engel, and R. Dubbelman Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours Radiother Oncol 80 2006 207 213
260. M. von Mehren, B.J. Giantonio, C. McAleer, R. Schilder, J. McPhillips, and P.J. O'Dwyer Phase I trial of ilmofosine as a 24 hour infusion weekly Invest New Drugs 13 1995 205 210
261. M. Wada, C.J. DeLong, Y.H. Hong, C.J. Rieke, I. Song, and R.S. Sidhu Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products J Biol Chem 282 2007 22254 22266
262. D. Wang, and R.N. Dubois Eicosanoids and cancer Nat Rev Cancer 10 2010 181 193
263. J. Wang, L. He, C.A. Combs, G. Roderiquez, and M.A. Norcross Dimerization of CXCR4 in living malignant cells: control of cell migration by a synthetic peptide that reduces homologous CXCR4 interactions Mol Cancer Ther 5 2006 2474 2483
264. N. Whittaker, S. Bunting, J. Salmon, S. Moncada, J.R. Vane, and R.A. Johnson The chemical structure of prostaglandin X (prostacyclin) Prostaglandins 12 1976 915 928
265. M.R. Wieckowski, and L. Wojtczak Fatty acid-induced uncoupling of oxidative phosphorylation is partly due to opening of the mitochondrial permeability transition pore FEBS Lett 423 1998 339 342
266. G.H. Williams, and K. Stoeber The cell cycle and cancer J Pathol 226 2012 352 364
267. R.J. Wills, A. O'Leary, S.V. Givens, and M.L. Scheinbaum Trimoprostil plasma concentration-gastric acid inhibition relationships in duodenal ulcer patients J Clin Pharmacol 26 1986 48 54
268. L. Wojtczak, and P. Schonfeld Effect of fatty acids on energy coupling processes in mitochondria Biochim Biophys Acta 1183 1993 41 57
269. B.C. Wong, W.P. Wang, C.H. Cho, X.M. Fan, and M.C. Lin 12-Lipoxygenase inhibition induced apoptosis in human gastric cancer cells Carcinogenesis 22 2001 1349 1354
270. S. Wongtangtintharn, H. Oku, H. Iwasaki, M. Inafuku, T. Toda, and T. Yanagita Incorporation of branched-chain fatty acid into cellular lipids and caspase-independent apoptosis in human breast cancer cell line, SKBR-3 Lipids Health Dis 4 2005 29
271. P.V. Woolley, C.J. Schultz, G.I. Rodriguez, R.A. Gams, K.W. Rowe Jr., and M.L. Dadey A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma Invest New Drugs 14 1996 219 222
272. H.W. Wu, H.F. Li, X.Y. Wu, J. Zhao, and J. Guo Reactive oxygen species mediate ERK activation through different Raf-1-dependent signaling pathways following cerebral ischemia Neurosci Lett 432 2008 83 87
273. H. Xia, R.S. Nho, J. Kahm, J. Kleidon, and C.A. Henke Focal adhesion kinase is upstream of phosphatidylinositol 3-kinase/Akt in regulating fibroblast survival in response to contraction of type I collagen matrices via a β1 integrin viability signaling pathway J Biol Chem 279 2004 33024 33034
274. G. Yan, S. Chen, B. You, and J. Sun Activation of sphingosine kinase-1 mediates induction of endothelial cell proliferation and angiogenesis by epoxyeicosatrienoic acids Cardiovasc Res 78 2008 308 314
275. Z. Yang, S. Liu, X. Chen, H. Chen, M. Huang, and J. Zheng Induction of apoptotic cell death and in vivo growth inhibition of human cancer cells by a saturated branched-chain fatty acid, 13-methyltetradecanoic acid Cancer Res 60 2000 505 509
276. A. Zetterberg, and O. Larsson Kinetic analysis of regulatory events in G1 leading to proliferation or quiescence of Swiss 3T3 cells Proc Natl Acad Sci U S A 82 1985 5365 5369
277. B. Zhang, H. Cao, and G.N. Rao Fibroblast growth factor-2 is a downstream mediator of phosphatidylinositol 3-kinase-Akt signaling in 14,15-epoxyeicosatrienoic acid-induced angiogenesis J Biol Chem 281 2006 905 914
278. C. Zhang, and D.R. Harder Cerebral capillary endothelial cell mitogenesis and morphogenesis induced by astrocytic epoxyeicosatrienoic acid Stroke 33 2002 2957 2964
279. G. Zhang, D. Panigrahy, L.M. Mahakian, J. Yang, J.Y. Liu, and K.S. Stephen Lee Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis Proc Natl Acad Sci U S A 110 2013 6530 6535
280. Z. Zhao, G.L. Araldi, Y. Xiao, A.P. Reddy, Y. Liao, and S. Karra Synthesis and evaluation of novel pyrazolidinone analogs of PGE2 as EP2 and EP4 receptors agonists Bioorg Med Chem Lett 17 2007 6572 6575